A phase II trial of Capecitabine (X) and Irinotecan (I) in a biweekly schedule in patients with untreated advanced colorectal cancer (ACRC)

被引：0
|
作者：
Garcia-Alfonso, P.
Perez MAnga, G.
Gonzalez, M. C.
Lopez, P.
Gonzalez, E.
Belon, J.
Molina, M.
Pachon, V.
Iglesias, L.
Siso, I.
机构：
[1] Hosp Univ Gregorio Maranon, Med Oncol Serv, Madrid, Spain
[2] Hosp Mostoles, Med Oncol Serv, Madrid, Spain
[3] Hosp Univ Virgen Nieves, Med Oncol Serv, Granada, Spain
[4] Hosp Gen Segovia, Med Oncol Serv, Segovia, Spain
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [1] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [2] Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC)
    Ahn, JB
    Jung, KH
    Park, YS
    Kim, YH
    Chang, HJ
    Sohn, DK
    Lim, SB
    Choi, HS
    Jeong, SY
    Park, JG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 299S - 299S
  • [3] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [4] Capecitabine (X) and Irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastasic colorectal cancer (MCRC): interim analysis of a phase II study
    Garcia-Alfonso, Pilar
    Gonzalez, M. C.
    Gonzalez, E.
    Molina, M.
    Monoz, A.
    Abad, G.
    Garcia, S.
    Lopez, P.
    Belon, J.
    Perez-Manga, G.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 89 - 89
  • [5] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [6] Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer
    Bajetta, Emilio
    Verzoni, Elena
    Ferrario, Erminia
    Dotti, Katia
    Gevorgyan, Arpine
    Celio, Luigi
    [J]. TUMORI JOURNAL, 2009, 95 (01): : 43 - 47
  • [7] Capecitabine and irinotecan as first line therapy in advanced colorectal cancer (ACRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Usset, A.
    Pepe, A.
    Calabria, C.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
  • [8] Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer
    Pavia, OA
    Cangiano, J
    Crisostomo, R
    Caceres, W
    Barranco, E
    Wright, M
    Antonia, T
    Antonia, S
    Sullivan, D
    Garrett, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 307S - 307S
  • [9] Phase I/II trial of dose reduced capecitabine in elderly or frail patients with untreated advanced colorectal cancer.
    Breadner, Daniel Adam
    Welch, Stephen
    Jonker, Derek J.
    Klimo, Paul
    Cripps, M. Christine
    Biagi, James Joseph
    Lam, Wendy
    Whiston, Frances
    Stitt, Larry
    Vincent, Mark David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [10] Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer
    Rosati, G.
    Cordio, S.
    Caputo, G.
    Condorelli, S.
    Germano, D.
    Mattina, M.
    Amadio, P.
    Reggiardo, G.
    Manzione, L.
    [J]. JOURNAL OF CHEMOTHERAPY, 2007, 19 (05) : 570 - 576
12345